Portal de Periódicos da CAPES

c-Met as a Prognostic Marker in Gastric Cancer: A Systematic Review and Meta-Analysis

2013; Public Library of Science; Volume: 8; Issue: 11 Linguagem: Inglês

10.1371/journal.pone.0079137

1932-6203

Shan Yu, Yiyi Yu, Naiqing Zhao, Jianlan Cui, Wěi Li, Tianshu Liu,

Peptidase Inhibition and Analysis

Backgroundc-Met has been recognized as an important therapeutic target in gastric cancer, but the prognostic property of the c-Met status is still unclear. We aimed to characterize the prognostic effect of c-Met by systematic review and meta-analysis. MethodsWe identified 15 studies assessing survival in gastric cancer by c-Met status. Effect measure of interest was hazard ratio (HR) for survival. Meta-regression was performed to estimate the relationship between HR and disease stage. Random-effects meta-analyses were used to account for heterogeneity. Results15 eligible studies provided outcome data stratified by c-Met status in 2210 patients. Meta-analysis of the HRs indicated a significantly poorer Os in patients with high c-Met expression (average HR=2.112, 95%CI: 1.622–2.748). Subgroup analysis showed the prognostic effect of c-Met was identical in protein-level and gene-level based methodology. The same effect was also seen in Asian and Western ethnicity subgroup analysis. Meta-regression showed HR was not associated with disease stage. ConclusionsPatients with tumors that harbor high c-Met expression are more likely to have a worse Os, with this prognostic effect independent of disease stage. c-Met status should be evaluated in clinical prognosis.